Shire plc Shire Plc : Directorate Change

FeaturesDow Jones Newswires


Directorate Change

Continue Reading Below

Dublin, Ireland - January 19, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG)

(the "Company") announces that Thomas Dittrich will assume his role as

Chief Financial Officer, and become an Executive member of the Board of

Directors and a member of the Executive Committee, on March 19, 2018.

This announcement is made in compliance with LR 9.6.12.

For further information please contact:

Investor Relations

Christoph Brackmann +41 795 432 359

Sun Kim +1 617 588 8175

Robert Coates +44 203 549 0874


Lisa Adler +1 617 588 8607

Katie Joyce +1 781 482 2779


About Shire

Shire is the global leader in serving patients with rare diseases. We

strive to develop best-in-class therapies across a core of rare disease

areas including hematology, immunology, genetic diseases, neuroscience,

and internal medicine with growing therapeutic areas in ophthalmics and

oncology. Our diversified capabilities enable us to reach patients in

more than 100 countries who are struggling to live their lives to the


We feel a strong sense of urgency to address unmet medical needs and

work tirelessly to improve people's lives with medicines that have a

meaningful impact on patients and all who support them on their journey.

This announcement is distributed by Nasdaq Corporate Solutions on behalf

of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Shire plc via Globenewswire

(END) Dow Jones Newswires

January 19, 2018 05:15 ET (10:15 GMT)